28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
SUVR using the whole cerebellum as the reference region and centiloid (CL) cutoffs for early and established amyloid pathology were 1.10 (13.5 CL) and 1.24 (35.7 CL), respectively. 5 key findings →
Participants: 287 Evidence: low
Full summary, score breakdown and related studies → Original source
Four of the 17 patients (23.5%) had amyloid-β pathology based on the overall pathology read and also showed increased [(18)F]flutemetamol uptake. [(18)F]Flutemetamol standardized uptake values from the biopsy site were significantly associated with biopsy specimen amyloid-β levels (Pearson's r = 0.67; p = 0.006). 5 key findings →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source
Aβ1-42, tTau and pTau (but not Aβ1-40) and the ratios with Aβ1-42 had good diagnostic agreement with 18 F-Florbetapir PET. 4 key findings →
Participants: 35 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Amyloid-PET presented higher diagnostic accuracy, sensitivity, and NPV than CSF Aβ1-42 but not Aβ42/40 ratio. 5 key findings →
Participants: 148 Evidence: low
Full summary, score breakdown and related studies → Original source
In the negative images of the HS group, the contrast between the white matter and the gray matter was high in the FMM PET images, while striatal uptake was relatively higher in the FPN PET images. 5 key findings →
Participants: 605 Evidence: low
Full summary, score breakdown and related studies → Original source
Twenty-five/38 (65.8%) amyloid PET/CT scans resulted positive for amyloid deposition. 5 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source
We assessed the severity of amyloid-β accumulation and white matter lesions (WML) in the brain, and their association with cognitive decline, in patients (n = 47) with Alzheimer's disease (AD). 4 key findings →
Participants: 47 Evidence: low
Full summary, score breakdown and related studies → Original source
The neuropathology of Parkinson's disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. 2 key findings →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
Multimodal biomarkers may identify former contact sports athletes with repeated concussions and at risk for dementia. 3 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD), affecting nearly 6.5 million people, is the fifth leading cause of death in individuals 65 years or older in the USA. 4 key findings →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source
As of 2023, it is estimated that 6.7 million individuals in the United States live with Alzheimer's disease (AD). 3 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
WMH volume within the inferior fronto-occipital fasciculus (IFOF) was the highest among all tract ROIs and associated with reduced FC in IFOF-connected DMN areas, independently of global AV-45 PET. 3 key findings →
Participants: 78 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with AD were clustered into 4 subtypes reproducibly, which included those with 1) diffuse and mild functional connectivity disruption (subtype 1), 2) predominantly decreased connectivity in the default mode network accompanied by an increase in the prefrontal circuit (subtype 2), 3) predominantly decreased connectivity in the anterior cingulate cortex accompanied by an increase in prefrontal cortex connectivity (subtype 3), and 4) predominantly decreased connectivity in the basal ganglia accompanied by an increase in prefrontal cortex connectivity (subtype 4). 3 key findings →
Participants: 809 Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive and visual functions including visuospatial processing, visual perception, episodic memory, and naming were impaired among PCA patients. 5 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source
Reductions of FALFF in temporal regions, especially the left superior temporal gyrus (STG) in MCI patients, were linked to decreased RNFL thickness and increased FAZ area significantly. 5 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
We found no disease effects on retinal vascular measures (all β's < |0.15|, all P > .2), adjusted for confounders. 3 key findings →
Participants: 48 Evidence: low
Full summary, score breakdown and related studies → Original source
The dominant theory of Alzheimer disease (AD) has been that amyloid-β (Aβ) accumulation in the brain is the initial cause of the degeneration leading to cognitive and functional deficits. 3 key findings →
Participants: 144 Evidence: low
Full summary, score breakdown and related studies → Original source
All measured CSF complement proteins were increased in AD versus CU subjects, with C4a displaying the most robust increase. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Comparison of SUVR in different brain regions demonstrated significant differences in the temporal, occipital and cerebellar cortices. 4 key findings →
Participants: 830 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 275,144 initiators of DPP-4 inhibitors or sulfonylureas, followed for 750,846 person-years, DPP-4 inhibitors were associated with a reduced dementia risk compared with sulfonylureas (4.4 vs. 5.7 events per 1000 person-years; HR 0.77, 95% CI 0.71-0.85). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson's disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
AChEI therapy had a significant effect on the percentage of stage 1 (p = 0.01) and stage 2 (p = 0.03) sleep. 5 key findings →
Participants: 41 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 157 subjects with a mean age of 71.8 (±7.7) included in this study, 76 individuals were stratified as metformin users. 5 key findings →
Participants: 157 Evidence: low
Full summary, score breakdown and related studies → Original source
Both groups were comparable in age (mean = 74 ± 7.2 years in the placebo group and 75 ± 7.4 in the intervention group) and in other demographics. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →